Table 4.

Multivariate analysis of MAPK phosphorylation, clinicopathological characteristics and cancer-specific survival in patients with colorectal cancer (n = 606)

	Multivariate HR (95% CI)	p
All patients (n = 606)
TNM stage (I/II/III)	1.87 (1.44–2.45)	<0.001*
Differentiation (moderate or well/poor)	1.10 (0.69–1.75)	0.703
Venous invasion (absent/present)	1.53 (1.13–2.07)	0.006*
Margin Invovlement (no/yes)	1.69 (1.05–2.73)	0.032*
Peritoneal invovlement (no/yes)	1.79 (1.31–2.45)	<0.001*
Proliferation index (low/high)	0.81 (0.60–1.10)	0.178
Tumour stroma percentage (low/high)	1.43 (1.04–1.99)	0.030*
Klintrup–Makinen grade (weak/strong)	0.64 (0.48–0.88)	0.030*
TILs (absent/present)	0.48 (0.30–0.77)	0.002*
mGPS (0/1/2)	1.57 (1.30–1.91)	<0.001*
Nuclear pERK (low/high)	0.65 (0.48–0.88)	0.004*
Combined nuclear pERK/p-p38 score (both low or one high/both high)	0.61 (0.45–0.82)	0.001*
MMR-competent BRAF mutant patients (n = 136)
TNM stage (I/II/III)	1.32 (0.74–2.38)	0.351
Venous invasion (absent/present)	2.58 (1.37–4.86)	0.003*
Margin Invovlement (no/yes)	4.45 (1.45–13.70)	0.009*
Peritoneal invovlement (no/yes)	0.95 (0.48–1.89)	0.887
Klintrup–Makinen grade (weak/strong)	0.72 (0.31–1.65)	0.436
TILs (absent/present)	0.42 (0.17–1.02)	0.054
mGPS (0/1/2)	2.66 (1.78–3.98)	<0.001*
Nuclear pERK (low/high)	0.52 (0.28–0.98)	0.042*
Combined nuclear pERK/p-p38 score (both low or one high/both high)	0.58 (0.31–1.06)	0.077
Stage III MMR-competent BRAF mutant patients (n = 53)
Venous invasion (absent/present)	1.17 (0.43–3.15)	0.762
Margin Invovlement (no/yes)	6.59 (1.21–35.87)	0.029*
Klintrup–Makinen grade (weak/strong)	0.19 (0.02–1.44)	0.107
TILs (absent/present)	0.21 (0.03–1.69)	0.143
mGPS (0/1/2)	3.01 (1.58–5.73)	0.001*
Nuclear pERK (low/high)	0.16 (0.06–0.44)	<0.001*
Combined nuclear pERK/p-p38 score (both low or one high/both high)	0.34 (0.10–1.19)	0.091

*Significant difference